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Nicotinic agonistsWhile there is some evidence that changes in nicotinic acetylcholine receptor (nAChR) subunits confer
resistance to levamisole in gastrointestinal helminth parasites, the exact nature of the resistance
mechanism(s) is unclear. We utilised the presence of a resistant fraction within the Wallangra 2003
isolate of Haemonchus contortus larvae in order to subdivide the population into three subpopulations
of larvae able to survive increasing concentrations of the drug. We then measured gene expression levels
in the subpopulations and the larval population as a whole, focusing on genes encoding the subunit com-
ponents of levamisole-sensitive receptors, genes encoding ancillary proteins involved in receptor assem-
bly, and P-glycoprotein (P-gp) genes. The subpopulation surviving the lowest levamisole concentration
showed increases of 1.5- to 3-fold in a number of P-gp genes (Hco-pgp-3, -4, -10, and -14) alongside
unchanged receptor genes, compared to the whole Wallangra larval population. On the other hand, the
subpopulation surviving the intermediate levamisole concentration showed an increase in only a single
P-gp (Hco-pgp-14), alongside decreases in some receptor subunit (Hco-unc-63a) and ancillary protein
genes (Hco-unc-50, Hco-ric-3.1 and 3.1). The subpopulation surviving the highest levamisole concentra-
tion showed further decreases in receptor subunit genes (Hco-unc-63a and Hco-unc-29 paralogs) as well
as genes involved in receptor assembly (Hco-unc-74, Hco-unc-50, Hco-ric-3.1 and 3.1), alongside no
increased P-gp gene levels. This suggests a biphasic pattern of drug resistance in the larvae of this worm
isolate, in which a non-speciﬁc P-gp-mediated mechanism confers low levels of resistance, while higher
level resistance is due to altered receptor subunit composition as a result of changes in both subunit
composition and in the levels of proteins involved in receptor assembly.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The use of anthelmintics for the control of intestinal parasites of
livestock over the last 50 years has led to the development of resis-
tance to each of the major chemical groups (McKellar and Jackson,
2004; Wolstenholme et al., 2004; Geary et al., 2012). The discovery
of new drug compounds to facilitate the management of resistance
is a slow and costly process that results in few novel compounds
being released (Besier, 2007; Woods and Knauer, 2010). Hence,
there is a need to manage the use of existing drugs in such a
way as to minimise the impact of resistance, for example through
the use of diagnostics to inform on the resistance status of worm
populations present on speciﬁc properties, and hence inform onwhich drugs are still likely to be effective. A sensitive molecular
test would be valuable for such resistance diagnostic purposes
(Prichard et al., 2007). However, before such a test can be designed,
an understanding of the mechanism or mechanisms of resistance
to a particular anthelmintic or anthelmintic class is required, or
at the very least the invariable presence of a genetic marker for
that resistance. In addition, elucidating the mechanism/s of resis-
tance may provide a better understanding of the rate at which
resistance may emerge, as well as providing a tool to study parasite
biology and drug targets (Sangster et al., 2005).
The cholinergenic anthelmintics, levamisole and pyrantel, act as
agonists at nicotinic acetylcholine receptors (nAChRs). A subset of
these receptors, known as the L-type receptors, are preferentially
activated by levamisole and pyrantel (Martin et al., 2012). Activa-
tion of this L-type nAChR by the drug leads to sustained neuromus-
cular depolarization and spastic paralysis (Martin et al., 1997),
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and leading to their expulsion from the host. The nAChRs are
composed of ﬁve subunits forming a ring in the membrane with
a central ion channel pore (Levandoski et al., 2005). The subunits
are classiﬁed as subunits; those bearing two vicinal cysteines
(unc-63, unc-38, acr-8) or b (non-a) subunits that lack the cysteines
(unc-29, lev-1) (Martin et al., 2012). Previous reports on mecha-
nisms of levamisole and pyrantel resistance in Haemonchus contor-
tus, Teladorsagia circumcincta, Trichostrongylus colubriformis and
Ancylostoma caninum have suggested a role for changes in the
expression of a number of nAChR subunit genes: reduced tran-
scription of unc-63a (Kopp et al., 2009; Sarai et al., 2013), reduced
transcription of unc-38 (Kopp et al., 2009), reduced transcription of
unc-29 (Kopp et al., 2009; Sarai et al., 2013), the presence of
Hco-acr-8b (Fauvin et al., 2010; Williamson et al., 2011), and the
presence of Hco-unc-63b (Neveu et al., 2010). Although not re-
ported to date from studies of parasitic nematodes, it is possible
that resistance may also be conferred by changes in ancillary pro-
teins, RIC-3, UNC-74 and UNC-50, that are known to be essential
for the proper formation, function and transport of the levamisole
receptor, and for which mutations in Caenorhabditis elegans are
known to confer resistance to levamisole (Gottschalk et al.,
2005). Moreover, drug efﬂux mechanisms such as P-glycoproteins
(P-gps) are involved in multidrug resistance in a variety of organ-
isms, including helminths, and have been implicated in resistance
to benzimidazoles and macrocyclic lactones (Kerboeuf et al., 2003;
Blackhall et al., 2008; Lespine et al., 2012).
Sarai et al. (2013) showed that larvae of the Wallangra 2003
(WAL) isolate of H. contortus exhibited a distinctive plateau in
response to levamisole in larval development assays, indicating
the presence of a highly resistant fraction accounting for approxi-
mately 10–15% of the total population. While the bulk of the pop-
ulation behaved in a similar manner to susceptible worms in the
larval development assay (equivalent IC50 values) the presence of
this resistant fraction resulted in a signiﬁcant shift in IC95 (13-fold
higher than the susceptible isolate). The authors suggested that it
might be difﬁcult to associate gene transcription patterns with
resistance in such heterogeneous isolates as the average transcrip-
tion levels in a sample of worm larvae derived from the whole
population might not be indicative of levels in the resistant frac-
tion within the population. Considering that this resistant fraction,
under further drug selection pressure, will most likely over time
become the dominant phenotype, ascertaining the differences be-
tween the resistant fraction and the bulk of the population might
give an indication of the genetic changes occurring in the early
stages in the development of resistance. Such changes would
therefore be the most critical to monitor in order to detect increas-
ing levels of resistance.
A signiﬁcant feature of all the parasitic nematode nAChR sub-
unit gene expression studies described above has been the fact that
they involved the comparison of genotypes or gene expression pat-
terns between populations showing different levels of resistance,
but also differing signiﬁcantly in genetic background. Field-derived
isolates showing resistance to the drug have most often been com-
pared to susceptible isolates collected from different geographical
regions, and/or from time periods several decades earlier than the
resistant isolate. Hence, the differences seen in gene expression
levels could be related to these diverse genetic backgrounds rather
than being speciﬁcally associated with their level of susceptibility
to the drug. The present study aimed to circumvent this issue to
some degree by subdividing a single ﬁeld-derived worm popula-
tion solely on the basis of the ability of subpopulations to survive
exposure to levamisole in vitro, and then comparing gene tran-
scription patterns between the whole population and the various
subpopulations. The heterogeneity in response to levamisole
shown by WAL larvae described above provided an opportunityto subdivide the population based on in vitro levamisole sensitivity.
Kotze et al. (2012) recently utilised such an experimental design in
subdividing the WAL isolate on the basis of susceptibility of larvae
to thiabendazole in vitro, followed by genotyping of a beta-tubulin
gene in the survivors at each drug concentration. This allowed the
authors to link speciﬁc SNP frequencies to relative drug resistance
levels shown by the different subpopulations.
The present study therefore aimed to recover larvae from the
levamisole-resistant fraction present within the WAL isolate, at
three separate levels of drug exposure, and to compare these
subpopulations to each other and to the WAL population as a
whole. We measured gene transcription levels for putative subunit
constituents of the levamisole sensitive receptor (Hco-unc-38,
Hco-unc-29.1–29.4, Hco-unc-63a, Hco-unc-63b, Hco-lev-1, Hco-acr-
8a and Hco-acr-8b) that have previously been implicated in resis-
tance, as well as two further nAChR subunit genes (Hco-acr-16
and Hco-acr-26). In addition, given their potential role in resis-
tance, we measured transcription levels of four ancillary protein
genes (Hco-unc-50, Hco-unc-74, Hco-ric-3.1 and Hco-ric-3.2)
(Martin et al., 2012), and nine P-gp genes.2. Materials and methods
2.1. Collection of worms and eggs
The Kirby 1986 and Wallangra 2003 (WAL) isolates of H. contor-
tus were maintained in sheep at the McMaster Laboratory, CSIRO
Livestock Industries, Armidale, New South Wales (NSW), Australia.
All animal procedures were approved by the F.D. McMaster Animal
Ethics Committee, CSIRO Animal, Food and Health Sciences (Ani-
mal ethics approval number 12/18). The Kirby isolate is susceptible
to all commercial anthelmintics (Albers and Burgess, 1988). The
WAL isolate was derived from a worm population in the New Eng-
land region of Northern NSW in 2003 (Love et al., 2003) that was
resistant to levamisole (efﬁcacy 79%), as well as benzimidazoles,
closantel and short-acting macrocyclic lactones, such as ivermec-
tin. Further selection pressure was applied to this isolate by use
of a full dose of Cydectin (active ingredient moxidectin) over at
least ﬁve subsequent generations. For the present study, sheep
were infected with this isolate and were subsequently treated with
a full dose of Cydectin 21 days after infection. After a period of at
least 6 weeks had elapsed since the Cydectin dose, faeces were col-
lected at various times for recovery of eggs.
Eggs were extracted from faeces by passage through two sieves
(250 and 75 lm), followed by centrifugation within a sugar gradi-
ent (10% and 25%). Eggs were recovered from the interface be-
tween the sucrose layers and washed over a 25 lm sieve with
water to remove the sucrose, before being treated with bleach
brieﬂy as described by Kotze et al. (2009). The eggs were washed
thoroughly to remove the bleach and were then ready for use in
larval assays or for in vitro drug selection.2.2. Larval development assay
An in vitro larval development assay (LDA), as described by
Gill et al. (1995) was used to characterize the WAL isolate with
respect to levamisole response. Stock drug solution was serially
diluted 2-fold in DMSO and 2 ll aliquots were added to a 96-well
plate with a ﬁnal drug concentration ranging from 10 to 0.0049 lg/
ml. 200 ll of 2% agar (Davis Gelatine Co., powdered agar Grade J)
was dispensed into each well, giving a ﬁnal DMSO concentration
of 1%. Plates were stored at 4 C for up to a fortnight and
re-equilibrated to room temperature before use. 30 ll of egg
suspension comprising of 3500 eggs/mL with amphotericin B
(ﬁnal concentration 25 ll/mL) and tylosin tartare (ﬁnal
Fig. 1. Response of Kirby and Wallangra 2003 isolates of H. contortus to levamisole
in larval development assays. Each data point represents mean ± SD, n = 9 assays for
levamisole (pooled data from three separate experiments, each with assays in
triplicate). Arrows indicate the drug concentrations used for subsequent population
subdivision experiments with the Wallangra isolate.
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et al., 2009). Plates were enclosed within a zip lock bag and incu-
bated at 26 C overnight. An aliquot of a live culture of Escherichia
coli was then added to each well (as described by Kotze et al.,
2009), and the plates were returned to the incubator for a further
5 days. The larvae were then killed using Lugol’s iodine solution
(10 ll per well). Numbers of L3 and total larvae were counted for
each well and the percentage of L3 larvae calculated for each well.
These values were then expressed as a percentage of the mean of
six control (no drug) wells on each assay plate (containing 1%
DMSO in agar only). Three replicate assays (each with triplicate
wells at each concentration) were performed for each drug with
each of the H. contortus isolates. Data from the assay was analyzed
using non-linear regression in GraphPad Prism 4™ (GraphPad
Software Inc., La Jolla, California, USA).
2.3. Isolation of sub-populations of WAL larvae showing increasing
levels of resistance
Data from larval development assays were examined in order to
identify concentrations of levamisole that resulted in larval devel-
opment levels of <20% compared to controls. The drug concentra-
tions selected for use in subsequent drug exposure experiments
were: 0.31, 1.25, and 2.5 lg/ml. Aliquots (29 ll) of the particular
levamisole solutions (prepared earlier for LDAs) required to give
these ﬁnal drug concentrations were added to wells of 6-well cul-
ture plates and 2 ml of 2% agar (Davis Gelatine Co., powdered agar
Grade J) was dispensed into each well (ﬁnal DMSO concentration of
1.45%). All wells on each plate received the same concentration of
levamisole. Control (no drug) plates were also prepared using
DMSO alone (1.45%). Egg solution, 1.4 ml, containing 30,000 eggs
with amphotericin B (ﬁnal concentration 11 ll/mL) and tylosin tar-
tare (ﬁnal concentration 343 ll/mL) was then added to each well. A
less concentrated egg suspension (with identical levels of ampho-
tericin and tylosin) was added to the wells of control plates to give
approximately 10,000 eggs per well. Plates were enclosed within a
zip lock bag and incubated at 26 C overnight. An aliquot of a live
culture of E. coli was then added to each well (Kotze et al., 2009),
and the plates were returned to the incubator for a further 5 days.
The larvae from each well on a plate were then collected by ﬂush-
ing the contents of all 6 wells into a beaker with water. The larvae
were placed onto the ﬁrst of a series of sieves (40 lm followed by
25 lm followed by 20 lm) and allowed to migrate through over
sequential 24 h periods in order to remove as many dead larvae
as possible. After each 24 h period, the larvae that had migrated
through the sieve were collected and placed onto the next sieve.
Larvae were collected from below the last sieve, washed again in
water, counted, and snap frozen in groups of 5000 in liquid nitro-
gen for RNA extraction.
2.4. Isolation of RNA and cDNA synthesis
RNA was extracted using Trizol LS™ (Invitrogen) as per the
manufacturer’s instructions, followed by treatment with TurboDN-
ase™ (Ambion). cDNA synthesis was performed on extracted RNA
with Superscript III™ reverse transcriptase (Invitrogen) according
to the manufacturer’s instructions. cDNA was diluted to a concen-
tration of 2.5 ng/ll for downstream applications. For each of the
sub-populations, cDNA was generated from three separate samples
of larvae for subsequent gene expression analysis.
2.5. Quantitative PCR
The primers used for quantitative PCR of a number of nAChR,
ancillary protein and P-gp genes were as described by Sarai et al.
(2013) (see Supplementary Tables 1 and 2). Three housekeepinggenes (GAPDH, Actin & 18S) were employed as reference for the
determination of relative expression levels. A Viia7 thermocycler
(Applied Biosystems) was used, with the SYBR Green dye system
(Applied Biosystems) and the following PCR cycling conditions:
50 C for 2 min, 95 C for 10 min, followed by 40 cycles 95 C for
15 s, 60 C for 1 min, 95 C for 2 min, 60 C for 15 sec. Three sepa-
rate extractions of each WAL subpopulation, as described earlier,
were examined, with each PCR reaction run in quadruplicate. As
reported earlier by Sarai et al. (2013), reaction efﬁciencies, as
determined from standard curves using a series of 4, 5-fold cDNA
dilutions, were in the range between 76% and 99%. Melting curve
analysis of each primer pair identiﬁed the qPCR products to be
homogenous and direct sequencing of these products conﬁrmed
the speciﬁc ampliﬁcation of the target gene. Expression values
for each gene of each sub-population were referenced to the three
housekeeping genes using REST 2008 software in order to derive a
value for the expression of each gene in the resistant sub-popula-
tion of the WAL isolate compared to the entire WAL population.
Differences between the sub-populations and the WAL isolate
were then examined using a ‘ratio t-test’ on the log of the ratio
as described in the GraphPad Prism handbook. Differences among
the 3 subpopulations within each gene were analysed using
ANOVA on the ratio data.3. Results and discussion
Fig. 1 shows the dose response curves describing the effects of
levamisole on the development of H. contortus WAL larvae com-
pared to the susceptible Kirby isolate. The WAL isolate showed a
very low-level resistance to levamisole at the IC50 (resistance ratio
1.13). However this isolate showed the presence of a resistant
fraction of approximately 10–15% as indicated by the plateau in
the dose response at higher drug concentrations. This was reﬂected
in a higher resistance ratio at the IC95 of 17-fold. These data were
used to select drug concentrations for subsequent experiments to
subdivide the population into groups based on their ability to sur-
vive increasing concentrations of drug. The concentrations used in
these experiments are illustrated with arrows on Fig. 1.
The isolation of resistant sub-populations of WAL larvae in-
volved passage through three mesh sieves in order to separate live
and dead larvae (based on ability to migrate through the sieves)
after the 6-day larval development period in the presence of the
drug. Table 1 describes the subdivision process in terms of the
numbers of eggs that were incubated at the different levamisole
concentrations and the numbers and percentages of larvae
Table 1
Description of the process of recovering larvae following exposure to levamisole in larval development assays.
Larval recovery parameter Worm population
Untreated Wallangra Levamisole treated
0.31 lg/ml
lev
1.25 lg/ml
lev
2.5 lg/ml
lev
Total eggs (‘000s) Rep1 12.1 930 1002 1682
Rep2 10.4 648 648 2252
Rep3 15.8 1050 950 2722
Post-sieve survivors (‘000s) Rep1 7.3 6.8 5.9 4.6
Rep2 6.8 4.7 4.4 4.5
Rep3 8.4 7.0 4.8 5.1
Post-sieve survivors (%)* 60.43 ± 4.23a 0.68 ± 0.02b 0.59 ± 0.05b 0.22 ± 0.03c
Post-sieve dead larvae (%)* 8.33 ± 1.53a 24.00 ± 3.06b 20.00 ± 4.93b 29.33 ± 1.20b
* Data shown as mean ± S.E. (n = 3); values labelled with the same letter are not signiﬁcantly different (P = 0.05).
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only as they were based on the counting of aliquots taken from
initial (pre-treatment) egg suspensions containing very large num-
bers of eggs (up to 20,000/ml). While the percentage develop-
ment data from larval development assays had indicated that
6–15% of larvae should survive at the various levamisole concen-
trations, the process of sieving drastically reduced these numbers
by nearly 15-fold to give larval recoveries of 0.7%, 0.6% and 0.2%
at the three increasing levels of levamisole, respectively. A reduc-
tion in viable larvae was also observed in the control population,
with losses approaching 40% (60.5% recovery of live larvae). This
loss of control larvae may be expected due to failure of some eggs
to hatch, some death during the development phase in the assay
plates, as well as losses during the ﬂushing of larvae from the wells
and the transfer of larvae between the sequential migration steps.
These factors would have been further exacerbated for drug-
treated worm larvae by the presence of large numbers of dead
worms during the early migration steps that may have greatly
hampered migration, as well as the possibility that fully grown
worms (that would have been scored as L3 stage larvae in the
LDA, Fig. 1) might have been less ﬁt after development in the
presence of levamisole, and hence less able to migrate freely
through the various meshes. Nevertheless, despite the lower than
expected recovery of levamisole-exposed worms, it is apparent
from Table 1 that a high degree of drug pressure was imposed on
the population, with <1% of larvae recovered from drug assays
compared to >60% for control assays. The percentage recovery of
post-treatment survivors was equivalent at the concentrations of
0.31 and 1.25 lg/ml (0.7% and 0.6%, respectively), and then sig-
niﬁcantly lower at 2.5 lg/ml (0.2%, P < 0.05). Despite repeated
migration steps, a signiﬁcant number of dead larvae were still
present in the ﬁnal worm suspensions, most likely having simply
‘fallen’ through the mesh during the 24 h migration periods. It
was noted that these dead larvae were mostly very small (L1 or
early L2 stage). The percentages of dead larvae were approximately
equal in each of the drug-pressured populations (20–29%).
It should be noted that the subdivision process resulted in three
subpopulations with a degree of overlap. That is, while the survi-
vors of 2.5 lg/ml existed as a separate subpopulation, individuals
of this type also existed as a component of the population surviv-
ing 1.25 lg/ml, and, in turn, larvae that would have been able to
survive of 1.25 and 2.5 lg/ml existed as a component of the
subpopulation described as having survived at 0.31 lg/ml. There-
fore, the transition from 0.31 to 2.5 lg/ml represented smaller
and smaller subpopulations (in percentage terms) of more highly
resistant worms.
The relative levels of transcription of nAChR subunits, ancillary
proteins and P-gp genes in the subpopulations of worms recoveredfrom assays at different levels of levamisole are shown in Table 2.
Highlighted in colour within the Table are those genes that showed
a signiﬁcant change (P < 0.05) in expression in the drug-pressured
populations compared to the WAL population as a whole
(recovered from control assay plates). In addition, within each
gene, differences in expression between worms recovered from
the different drug concentrations are indicated with alphabetical
notation. Hco-unc-29.3 and Hco-acr-8b were beyond the levels of
detection in the quantitative PCR assays (that is, CT values >39).
Among the nAChR subunit genes, there were a number of
instances of reduced transcription in the drug-pressured worms
compared to the controls. In each case these decreases were seen
only at the highest drug concentration or in both the highest and
mid concentrations. Hence, for these genes, decreasing gene
expression was associated in each case with increasing drug con-
centration. Hco-unc-63a and Hco-acr-8a levels showed step-wise
decreases at the two highest levamisole concentrations, while
Hco-unc-63b, Hco-unc-29.2, Hco-unc-29.4 and Hco-unc-26 were all
lower than the control population in survivors of the highest
levamisole concentration. The greatest decrease was with Hco-
unc-29.4 which showed an almost 6-fold reduction in the most
highly drug-pressured subpopulation. Levels of Hco-unc-38 and
Hco-unc-63b were elevated at the lowest drug concentration, how-
ever they were unchanged compared to controls at the other two
concentrations for Hco-unc-38, and reduced at the highest
concentration for Hco-unc-63b. Previous studies on mechanisms
of levamisole/pyrantel resistance have focussed primarily on
changes in nAChR subunits in resistant isolates: reduced
transcription of unc-29 paralogs and unc-63a within H. contortus
(Kopp et al., 2009; Sarai et al., 2013) as well as down-regulation
of unc-38, -29 and -63 in A. caninum (Kopp et al., 2009), the
presence of truncated forms of Hco-unc-63 and Hco-acr-8
(Hco-unc-63b and Hco-acr8b, respectively) within some resistant
H. contortus isolates (Fauvin et al., 2010; Neveu et al., 2010;
Williamson et al., 2011). The results of the present study are in
agreement with some of these earlier reports in showing down-
regulation of some components of the levamisole-sensitive
nAChRs, namely Hco-unc-63a and the Hco-unc-29 paralogs.
The most consistent decreases in transcription in the levam-
isole-exposed subpopulations were observed in the ancillary pro-
tein genes (Table 2). Levels of Hco-ric-3.1 were decreased relative
to the control population at all levamisole drug concentrations,
while Hco-unc-50 and Hco-ric-3.2 were lower for the two highest
drug concentrations, and Hco-unc-74 was reduced at the highest
concentration. Studies with the free-living nematode C. elegans
have shown the essential role of these ancillary proteins in the
proper formation and functioning of levamisole receptors.
UNC-74 encodes a thioredoxin which is closely related to the
Table 2
Relative transcription of nAChR subunit, ancillary protein and P-glycoprotein genes in three resistant fractions of H. contortus Wallangra 2003 isolate compared to the whole
population.
⁄Data shown as mean ± S.E. n = 3 separate experiments; within each gene, values labelled with the same letter are not signiﬁcantly different (at P = 0.05); Statistical notation
for control samples is shown following the gene name; - indicates not detectable.
R.S. Sarai et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 77–84 81
82 R.S. Sarai et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 77–84human TMX3 protein (Haugstetter et al., 2005) and is likely to be
involved in the folding of AChRs. Early screens for resistance to
levamisole identiﬁed unc-74 as a key component for the
expression of L-type nAChRs within C. elegans (Lewis et al.,
1980). UNC-50 is required for the trafﬁcking of L-type receptors
to the cell surface and the normal synaptic transmission at the
neuromuscular junction and is ubiquitously expressed from early
embryogenesis to adulthood, localizing mostly to the Golgi appara-
tus. In the absence of UNC-50, L-type nAChRs are targeted to
lysozymes after they exit the endoplasmic reticulum and are
degraded, thereby resulting in loss of function (Eimer et al.,
2007). RIC-3 is a chaperone protein required for proper receptor
assembly and functional expression in the endoplasmic reticulum.
Alongside UNC-74 and -50, Boulin et al. (2011) demonstrated that
co-expression with RIC-3 was required for nAChR activity in
C. elegans and in Xenopus oocytes. Previous studies had identiﬁed
the protein encoded by RIC-3 as essential for maturation of
levamisole sensitive vulval muscle AChRs, for the maturation of
the EAT-2 AChR that enables pharyngeal pumping and that RIC-3
may act at a postsynaptic site (Halevi et al., 2002). Recent immuno-
histochemical studies have also shown that mutations in RIC-3
caused a reduction in cell surface expression of LEV-1 (Gottschalk
and Schafer, 2006) which may result in decreased sensitivity to
levamisole. Further, RIC-3 has been shown to increase the func-
tional expression of the N-type nAChR subunits such as ACR-16
within Xenopus oocytes (Bennett et al., 2012). Although the speciﬁc
effects of the reduced transcript levels of these ancillary protein
genes described in the present study are not known, their essential
roles described above would suggest that their reduced transcrip-
tion would have signiﬁcant effects on the assembly and function of
nAChRs in the larvae able to survive and develop in the presence of
levamisole: reduced UNC-74 may interfere with the ability of
nAChRs to fold correctly, reduced UNC-50 may lead to a greater
targeting of receptors to the ER, followed by degradation, and
ﬁnally reduced RIC-3 may lead to disruption of receptor assembly.
All these effects may contribute to a reduced level of functioning
levamisole-sensitive nAChRs in the drug resistant worms, hence
reducing their sensitivity to the presence of levamisole during
the larval development phase of the life cycle. It is not clear
whether such reductions in levamisole-sensitive AChRs would
have ﬁtness costs for the resistant larvae. This was not tested in
the present study as we did not assess larval ﬁtness, except for
the ability of larvae that survived the levamisole exposure to then
migrate through the series of meshes.
A number of P-glycoprotein genes showed increases at the
lowest drug concentration (Hco-pgp-3, -4, -10 and -14), alongside
decreases or no change at the highest drug concentration
(Hco-pgp-2, -3, -10) (Table 2). The increases seen at 0.31 lg/ml
indicates that within the Wallangra population exists a subset of
larvae able to survive exposure to this level of levamisole that also
show elevated P-gp levels, suggesting that the efﬂux pumps may
contribute to the observed drug tolerance. In addition, the lack of
any increased P-gp in the worm larvae exposed to the two highest
drug concentrations suggests that the larvae able to survive 1.25
and 2.5 lg/ml levamisole do not utilise P-gp efﬂux pumps to sur-
vive the drug exposure. Little is known about the speciﬁc interac-
tion of levamisole with P-gps. Several imidazothiazole drugs have
been shown to be reversing agents for multidrug resistances
shown by mammalian cell lines suggesting that they can interact
with P-gps (Naito et al., 1998). More recently, Kerboeuf and Gueg-
nard (2011) found that levamisole stimulated P-gp activity in H.
contortus eggs, suggesting that the compound may bind to ’regula-
tory’ sites on nematode P-gps. James and Davey (2009) reported
that exposure of C. elegans to repeated selection pressure with
ivermectin resulted in resistance to this drug alongside some
cross-resistance to levamisole, as well as signiﬁcantly increasedexpression of P-gp genes. This suggested that the increased trans-
porter activity in the resistant worms had resulted in an increased
ability to transport both ivermectin and levamisole, hence high-
lighting the latter as a likely substrate for the worm P-gps.
De Graef et al. (2013) found that in vitro exposure of L3 Cooperia
oncophora to ivermectin resulted in increased expression of several
P-gp genes. This raises the question as to whether the P-gp expres-
sion increases observed in the present study represent constitutive
gene expression patterns in the levamisole-resistant larvae or are
the result of induction following exposure to the drug. We consider
that they most likely represent constitutive expression patterns as
it would be likely that maintenance of the L3 worms in a drug-free
environment for 72 h during the sieve migration period would
have resulted in the return of any induced gene expression to base-
line levels. While there is a deal of literature on the inducing effects
of various agents on P-gp expression, there is very little informa-
tion available on the time course of gene expression changes after
removal of the inducing agents; Fardel et al (1996) found that
expression of a P-gp in rat liver epithelial cells was signiﬁcantly in-
duced following exposure for 24 h to 3-methylcholanthrene, with a
return to almost basal levels 72 h after removal of the inducing
agent. However, the possibility remains that the increased P-gp
expression levels in levamisole-exposed larvae in the present study
was an induction phenomenon. This will require further experi-
mentation to clarify.
The gene expression changes shown in Table 2 suggest the
presence of a biphasic pattern of gene expression as the resistance
increases in WAL larvae: increased expression of P-gps is the
dominant change seen in worms able to survive the lowest drug
concentration, while reduced expression of receptor subunit and
assembly genes becomes signiﬁcant as levamisole resistance in-
creases. This suggests that two levels of resistance, each associated
with distinct gene expression changes, are present: non-speciﬁc
Pgp-mediated low-level resistance alongside target site changes
conferring higher levels of resistance. This observation aligns with
earlier levamisole resistance literature which reported that levam-
isole resistance existed in the ﬁeld in Australia in two forms de-
noted ‘moderate level resistance’ and ‘high level resistance’ based
on responses in larval development assays (Drenchrite Users
Guide, 1996, Horizon Technology, Australia).
The ability of organisms to exhibit multiple resistance mecha-
nisms which confer different levels of resistance has been docu-
mented for some time in insects (for example, Farnham, 1973).
Scott and Georghiou (1986) found that three mechanism were
responsible for pyrethroid resistance in a strain of houseﬂy: en-
hanced metabolism via the mixed function oxidase (MFO) system,
target-site insensitivity, and decreased cuticular penetration. The
major mechanism of resistance was the MFO-mediated detoxiﬁca-
tion. This multi-tiered nature of resistance has also been observed
with aphids (Puinean et al., 2010) and mosquitoes (Wood et al.,
2010) highlighting the role of a non-speciﬁc mechanism that con-
fers low-level resistance against a number of drug groups, along-
side speciﬁc mechanisms involving target site or detoxiﬁcation
enzyme changes which confer higher level resistance.
Sarai et al. (2013) highlighted the difﬁculty of detecting gene
expression changes associated with levamisole resistance when
examining pooled samples of larvae from isolates displaying a de-
gree of heterogeneity in response to the drug as shown byWAL lar-
vae. This was because the averaging of gene expression levels
across the whole population might mask changes that may confer
resistance in the highly resistant subpopulation seen with this iso-
late. A comparison of the gene expression data from Sarai et al.
(2013) with the present study is informative in this regard. The
earlier study found that no nAChR subunit showed reduced tran-
scription in pooled samples of WAL L3 stage larvae compared to
the Kirby isolate. This was in contrast to larvae of the LAWES and
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unc-63a in both isolates, and Hco-unc-29.2 and Hco-unc-29.4 in
LAWES) were reduced compared to Kirby. Importantly, in vitro
larval development assay dose responses for these two resistant
isolates were well displaced from the Kirby isolate at all drug con-
centrations (resistance ratios at the IC50 > 650). Hence, while the
earlier gene transcription measurements of WAL L3 stage worms
failed to detect any changes in this isolate compared to Kirby,
the present study indicates that at least some of the changes seen
in LAWES and LevR do indeed occur in the most resistant individ-
uals in the WAL isolate. This illustrates the effect of gene transcrip-
tion measurements across a whole population in masking changes
that may be present in a small number of resistant individuals. At
the early stages of the development of resistance to an anthelmin-
tic, the resistant genotype/phenotype is present at very low fre-
quencies in the population, and only these few individuals are
able to survive drug concentrations signiﬁcantly higher than the
‘normal’ susceptible range. The present study, in examining sub-
populations of worms able to survive drug concentrations signiﬁ-
cantly higher than the bulk of the population, has effectively
served as a model for the detection of the early stages of resistance.
It is most likely that over time and under further drug selection
pressure the genotypes and phenotypes possessed by the more
resistant fractions would become dominant. Hence, the present
study and that of Sarai et al. (2013) illustrate a limitation in the
use of gene expression-based tests to detect resistance at its early
stages where only a small fraction of the population are resistant.
This is in contrast to SNP-based methods which can detect changes
in allele frequencies at very low levels in a population (von
Samson-Himmelstjerna et al., 2009).
In conclusion, the present study suggests that reduced tran-
scription of genes coding for structural components of levam-
isole-sensitive receptors (Hco-unc-63a, -63b, Hco-unc-29 paralogs,
Hco-acr8a) as well as genes coding for proteins involved in the
assembly and functioning of the receptors (Hco-unc-74, Hco-unc-
50, Hco-ric-3.1 and 3.2) may play a signiﬁcant role in levamisole
resistance in larvae of a ﬁeld-derived isolate of H. contortus. In
addition, our data suggests a role for P-glycoproteins in worm lar-
vae within the population that show a lower level of resistance
than those characterised by the changes in receptor subunit and
receptor assembly genes. Importantly, our study design has al-
lowed us to associate gene expression patterns with levamisole
sensitivity among worms with similar genetic backgrounds using
subpopulations distinguishable from the whole population, and
from each other only, on the basis of their ability to survive drug
exposure in vitro. Though changes in expression patterns within
the larvae examined here may not be indicative of changes within
adult worms which will have a real impact on drug efﬁcacy in the
ﬁeld, this study provides a starting point to investigate variations
in gene expression patterns among adult worms differing in drug
sensitivity. An investigation into gene transcription patterns and
resistance status in adults cultivated from the resistant fractions
examined here would provide greater insight into the relationship
between resistance in this species at the larval and adult life stages.
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